Advertisement

Corrigendum to “A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia”

[ATH 162 (2002) 373–379]
      The author regrets that in the above paper, Table 2 was printed incorrectly; it is now reproduced correctly below.
      Table 2Changes in lipid parameters at the end of the study
      nPitavastatin mean [1] (95%LCL–UCL)nPravastatin mean [2] (95%LCL–UCL)95%CI of [1–2]
      TC120−28.0 (−29.6 to −26.4)105−13.8 (−15.6 to −12.0)−16.5 to −11.8
      LDL-C120−37.6 (−39.9 to −35.3)105−18.4 (−20.7 to −16.1)−22.5 to −15.9
      TG (≧150 mg/dl)
      TG represents the data of the patients with a baseline level of TG≧150 mg/dl.
      50−23.3 (−32.9 to −13.7)44−20.2 (−28.4 to −12.0)−16.1 to 9.8 (1), −∞ to 7.7 (2)
      HDL-C1208.9 (6.4–11.4)1059.8 (7.0–12.6)−4.7 to 2.9
      ApoA-I1147.2 (5.3–9.1)1017.5 (5.5–9.5)−3.1 to 2.5
      ApoA-II1144.2 (2.3–6.1)1015.7 (3.8–7.6)−4.2 to 1.1
      ApoB114−33.8 (−35.8 to −31.8)101−16.9 (−18.9 to −14.9)−19.7 to −14.1
      ApoC-II114−15.7 (−20.1 to −11.3)101−6.1 (−10.6 to −1.6)−15.9 to −3.1
      ApoC-III114−9.5 (−13.0 to −6.0)101−2.6 (−5.9 to 0.7)−11.8 to −2.1
      ApoE114−22.9 (−25.6 to −20.2)101−12.6 (−14.9 to −10.3)−13.8 to −6.6
      Lipoprotein (a)1142.1 (−4.0 to 8.2)1025.1 (0.1–10.1)−11.0 to 5.1
      The 95% CI of difference is shown in the upper line (1) and the non-inferiority is in the lower line (2).
      a TG represents the data of the patients with a baseline level of TG≧150 mg/dl.